European Case Law Identifier: | ECLI:EP:BA:2017:T023916.20170913 | ||||||||
---|---|---|---|---|---|---|---|---|---|
Date of decision: | 13 September 2017 | ||||||||
Case number: | T 0239/16 | ||||||||
Application number: | 05012711.7 | ||||||||
IPC class: | A61K 31/663 A61P 19/08 A61P 19/10 |
||||||||
Language of proceedings: | EN | ||||||||
Distribution: | D | ||||||||
Download and more information: |
|
||||||||
Title of application: | Method of administering bisphosphonates | ||||||||
Applicant name: | Novartis AG Novartis Pharma GmbH |
||||||||
Opponent name: | Generics [UK] Limited Sanovel Ilaç Sanayi ve Ticaret A.S. Taylor Wessing LLP |
||||||||
Board: | 3.3.01 | ||||||||
Headnote: | - | ||||||||
Relevant legal provisions: |
|
||||||||
Keywords: | Public availability of document (yes) Main and auxiliary request: novelty - (yes) Main and auxiliary request: inventive step - (no) |
||||||||
Catchwords: |
- |
||||||||
Cited decisions: |
|
||||||||
Citing decisions: |
|
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t160239eu1.html
Date retrieved: 17 May 2021